NEW YORK and SYDNEY, October 19, 2020, Beroni Group (“Beroni”) announced successful completion of SARS-CoV-2 pseudovirus neutralization assay in collaboration with GenScript Biotech Corporation (“GenScript”), a leading global biotechnology company.…
On August 4, 2020, Beroni Group Limited (“Beroni Group”) announced that it has signed an agreement with GenScript Biotech Corporation (“Genscript”) to collaborate in the development of a medical solution…
On July 10, 2020, Beroni Group Limited (“Beroni”), an international diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases,…
On 22nd May, the representatives of Huarong Securities Co., Ltd (“Huarong Securities”) including Mr. Minsheng Jian, General Manager of Enterprise Innovation Financing Department, Mr. Yuying Geng, General Manager of Business…
On 13th May, 2020, Beroni Group Co., Ltd. (Beroni Group) and Beijing Health Industrial Investment Management Co., Ltd. (BG Health) signed a strategic cooperation agreement to collaborate in fields of…
On May 11, 2020, Beroni Group is pleased to announce that its development of a medical solution using nanobody technology for the novel coronavirus (SARS-CoV-2), in collaboration with Tianjin University…
After official review, the Beroni’s SARS-CoV-2 IgG/IgM Antibody Detection Kit is confirmed to comply with the quality standards and safety requirements stated in the “Announcement on Further Strengthening the Quality…
On the morning of the last day of December in 2019, Beroni China held its 2019 Work Summary Meeting. Mr. Jacky Zhang, Executive Chairman of Beroni Group, senior management of…
On 7th December, the Third Precision Medicine & Medical Care and Aging International Forum (“Forum”) organized by the Silk-Road Industry and Finance International Alliance and Beroni Group Limited, and co-sponsored…
